Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRT6010 crossover biomarker study in healthy volunteers
NL-OMON37607Active, not recruiting
- Sponsor
- Grünenthal GmbH
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of GRT6010 in Neuralgia (2 arms), sponsored by Grünenthal GmbH. Primary endpoints: Leukocyte CD11b expression and Plasma nociceptin concentration. Started May 2012; status: active, not recruiting.
02
Drugs
GRT6010
03
Conditions
Neuralgia
Beyond the preview
Go deeper on NL-OMON37607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37607.